Delipid Extracorporeal Lipoprotein Filter From Plasma (DELP) for Acute Hemorrhagic Stroke

A trial with no phase registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 356 participants.

Also called NCT05128513

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 356 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05128513
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT05128513. Randomized; single masking; primary purpose treatment. Start 2022-01-14 (actual); primary completion 2027-04-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Delipid Extracorporeal Lipoprotein Filter From Plasma (DELP) for Acute Hemorrhagic Stroke
Condition
Hemorrhagic Stroke
Intervention (Device)
DELP
Lead sponsor
General Hospital of Shenyang Military Region (class: other)

Record details

Record id
cardio:ct-nct05128513
Content hash
306b75edbdc450f574935bd9adc469666c206da276b44839b8ae1db601a9ced6